Stock MOC MOLECURE S.A.
Add to a list
To use this feature you must be a member
Log inSign up

All News Molecure S.A.

Equities

MOC

PLONCTH00011

Market Closed - Warsaw S.E.
Other stock markets
 16:55:41 04/06/2024 BST 		5-day change 1st Jan Change
15.22 PLN -0.26% Intraday chart for Molecure S.A. +0.26% -21.95%
05-21 Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway CI
05-17 Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway
CI
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis
CI
Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I
CI
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Poland's Molecure Gets US FDA Clearance for Mid-stage Trial of Potential Pulmonary Sarcoidosis Treatment
MT
Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01
CI
Molecure S.A. announced that it has received PLN 49.968 million in funding
CI
Poland's Molecure Files Investigational New Drug Application with US FDA for Pulmonary Sarcoidosis Drug
MT
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Molecure S.A. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Poland's Molecure Doses First Patient in Cancer Treatment Trial
MT
Molecure Announces First Patient Dosed in Phase I Trial with Novel, First-In-Class Dual Arginase Inhibitor OATD-02 for the Treatment of Cancer
CI
Molecure S.A. Announces Management Changes
CI
Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022
AQ
Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland
CI
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Molecure S.A.(WSE:MOC) dropped from S&P Global BMI Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MOC Stock
  4. News Molecure S.A.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW